Retrospective Observations on the Ability to Diagnose and Manage Patients with Asthma through the Use of Impulse Oscillometry: Comparison with Spirometry and Overview of the Literature

Table 1

Patient Spirometry and IOS Baseline.

Asthma patient	Age	Inhaled steroid	Before FEV1	Post bronchodilator FEV1	% Chg	Before AX	Post bronchodilator AX	% Chg	Before R5	Post bronchodilator R5	% Chg	Before R15	After R15	% Chg
1	41	Mometasone furoate	4.03	3.27	−19.00%	11.98	6.94	−42.10%	4.12	3.41	−17.30%	3.2	2.62	−18.30%
2	41	Fluticasone/salmeterol	4.16	4.12	−1.00%	10.37	6.36	−38.70%	4.03	3.86	−4.10%	2.83	2.77	−1.90%
3	45	Ciclesonide	3.6	2.94	−18.30%	4.44	5.24	17.90%	2.78	2.47	−10.90%	1.99	1.64	−17.50%
4	78	Mometasone furoate	2.26	2.74	21.60%	7.05	3.13	−55.50%	2.79	72.2	−15.90%	1.87	1.74	−7.20%
5	65	Budesonide/formoterol	1.5	1.79	19.10%	6.22	3.81	−38.70%	3.02	2.36	−21.80%	2.07	1.69	−18.20%
6	71	Beclomethasone dipropionate	1.37	1.28	−6.40%	32.15	24.39	−24.20%	6.18	5.25	−15.00%	3.74	3.71	−1.10%
7	44	Budesonide/formoterol	3.54	3.87	9.20%	11.82	2.49	−78.90%	4.55	3.21	−29.40%	3.85	2.91	−24.40%
8	47	Mometasone furoate	2.18	2.65	21.40%	7.74	5.59	−27.80%	3.62	3.48	−3.90%	2.53	2.62	3.70%
9	59	Ciclesonide	2.26	2.26	0.20%	8.71	6.75	−22.50%	3.71	3.24	−12.60%	2.49	2.21	−11.00%
10	35	Mometasone furoate	3.81	4.01	5.10%	7.4	6.5	−12.20%	3.01	3.56	18.20%	2.32	2.46	5.80%
11	60	Mometasone furoate	1.91	1.95	2.40%	23.86	19.05	−20.20%	6.47	5.29	−18.20%	3.98	3.31	−16.80%
12	31	Ciclesonide	4.13	4.13	−0.10%	2.28	1.04	−54.60%	2.72	2.43	−10.60%	2.29	2.29	−0.30%
13	51	Budesonide/formoterol	1.97	1.85	−6.00%	14.32	11.78	−17.70%	4.64	4.14	−11.00%	2.72	2.64	−2.80%
14	29	Mometasone furoate	3.93	4.18	5.30%	4.08	2.99	−26.70%	2.39	2.45	2.60%	1.92	1.8	−6.20%
15*	36	Mometasone furoate	3.61	3.89	7.80%	6.32	4.59	−27.30%	3.14	3.37	7.20%	2.76	2.94	6.70%
16	51	Budesonide	2.32	2.36	1.90%	7.43	5.63	−24.30%	2.79	3.11	11.50%	2.29	2.39	4.20%
17	50	Budesonide	3.11	3.25	4.70%	3.05	1.88	−38.20%	3.63	3.05	−15.90%	3.19	2.67	−16.30%
18	83	Fluticasone/salmeterol	2.49	2.21	−11.30%	6.36	9.18	44.30%	2.25	2.66	18.20%	1.84	1.8	−2.20%
19	57	Fluticasone/salmeterol	1.91	1.94	1.50%	22.44	20.31	−9.50%	4.3	4.18	−2.80%	2.75	2.67	−3.20%
20	37	Mometasone furoate	3.78	3.51	−7.10%	7.41	5.34	−28.00%	3.69	3.37	−8.60%	2.85	2.66	−6.90%
21	51	Ciclesonide	2.64	2.73	3.50%	9.4	7.54	−19.80%	4.01	3.31	−17.40%	2.88	2.48	−14.00%
22	24	Mometasone furoate	3.95	3.72	−5.70%	5.55	2.95	−46.80%	2.92	2.41	−17.40%	2.17	1.91	−12.00%
23	35	Budesonide/formoterol	2.38	2.86	20.50%	6.23	2.35	−62.20%	3.56	2.18	−38.70%	3.15	1.95	−38.20%
24	61	Budesonide/formoterol	2.48	2.56	3.20%	10.87	9.11	−16.20%	3.86	3.58	−7.30%	2.62	2.43	−7.30%
25	33	Mometasone furoate	2.74	2.73	−0.30%	9.86	9.56	−3.00%	3.66	4.09	11.80%	2.41	2.49	3.30%
26	49	Mometasone furoate	2.96	2.99	1.20%	7.66	6.06	−20.80%	3.97	3.86	−2.90%	3.06	3.05	−0.10%
27	65	Fluticasone/salmeterol	1.73	1.87	7.90%	4.78	5.55	16.10%	2.97	3.99	34.20%	2.4	3.66	52.50%
28	31	Mometasone furoate	2.56	2.19	−14.40%	5.37	2.96	−44.90%	3.73	3.38	−9.40%	2.64	2.8	6.00%
29	74	Mometasone furoate	1.6	1.67	4.90%	14.06	11.15	−20.70%	3.65	3.23	−11.50%	2.54	2.38	−6.30%
30	54	Ciclesonide	2.36	2.7	14.10%	5.23	2.08	−60.20%	2.6	2.18	−15.90%	2.05	1.87	−8.80%
31	54	Ciclesonide	2.53	2.54	0.40%	9.46	7.24	−23.50%	2.85	2.76	−3.10%	1.94	1.87	−3.60%
32	53	Ciclesonide	3.01	3.1	3.10%	20.7	18.9	−8.70%	4.83	4.97	2.80%	3.28	3.17	−3.30%
33	60	Budesonide/formoterol	1.63	1.7	4.40%	15.32	4.46	−70.90%	4.91	3.83	−22.20%	3.9	3.34	−14.20%
34	80	Mometasone furoate	2.3	2.54	10.10%	19.97	5.98	−70.00%	4.2	2.97	−29.40%	2.85	2.29	−19.80%
35	65	Fluticasone/salmeterol	1.69	1.8	6.70%	16.32	7.38	−54.80%	4.45	3.41	−23.20%	2.95	2.47	−16.30%
36	71	Mometasone furoate	1.56	1.67	6.70%	5.68	7.31	28.80%	2.11	3.08	46.20%	1.7	2.42	42.20%
37	23	Fluticasone/salmeterol	3.36	3.74	11.30%	21.19	5.63	−73.40%	4.39	2.85	−35.00%	2.86	2.38	−16.90%
38	63	Beclomethasone dipropionate	2.73	2.77	1.60%	6.05	4.69	−22.40%	3.07	2.83	−8.00%	2.33	2.22	−4.90%
39	52	Budesonide	1.81	1.97	8.60%	15.74	6.46	−58.90%	3.8	2.66	−30.00%	2.4	1.72	28.20%

∗denotes patient that is referenced in Figure 1.